This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Smith+Nephew (SNN) to Acquire Orlando-Based Engage Surgical
by Zacks Equity Research
Smith+Nephew's (SNN) acquisition of Engage Surgical reinforces its growth strategy while expanding its Orthopaedic Reconstruction product line.
Smith+Nephew (SNN) Introduces Real Intelligence & CORI System
by Zacks Equity Research
Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.
Smith+Nephew (SNN) Rolls Out Robotic Assisted Surgical System
by Zacks Equity Research
Smith+Nephew's (SNN) CORI system enables each patient to have a knee replacement that is shape-matched and aligned to their specific anatomy.
Here's Why You Should Retain Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) owing to domestic growth in the spine business and robust demand for the HEDRON line of products.
Smith+Nephew (SNN) Releases New Features for Hip Arthroplasty
by Zacks Equity Research
Smith+Nephew (SNN) introduced the RI.HIP NAVIGATION software on the CORI Surgical System and announced the commercial availability of RI.INSIGHTS at the AAOS 2021 Annual Meeting.
Smith+Nephew's (SNN) New Device to Boost Patient Outcomes
by Zacks Equity Research
Smith+Nephew's (SNN) FAST-FLIX FLEX Meniscal Repair System to provide long-term benefits to patients.
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
Coronavirus Ups the Game for Robotic Surgery: 3 Stocks on Radar
by Sriparna Ghosal
Let's keep a watch on the potentially strong three MedTech stocks, namely SYK, ARAY and MDT with respect to robotic-assisted surgery that showed promises during the pandemic.
Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging
by Zacks Equity Research
Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.
Integra (IART) Sells Unprofitable Arm to Focus on Core Business
by Zacks Equity Research
Integra (IART) does not expect the selloff to have a material impact on its 2020 results.
Integra (IART) to Buy ACell, Expand Regenerative Capability
by Zacks Equity Research
Integra (IART) expects to close the ACell acquisition in the first quarter of 2021, subject to fulfilment of closing conditions.
Is Smith & Nephew (SNN) a Suitable Stock for Value Investors?
by Zacks Equity Research
Let's see if Smith & Nephew plc (SNN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Robot-Assisted Surgery Gains Momentum Amid Coronavirus
by Trina Mukherjee
Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.
Smith+Nephew Unveils Digital Platform to Boost Patient Care
by Zacks Equity Research
With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.
Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark
by Zacks Equity Research
We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.
Smith & Nephew's JOURNEY II UK Knee System Executes Surgeries
by Zacks Equity Research
The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.
Smith & Nephew's Study Outcomes for REGENETEN Encouraging
by Zacks Equity Research
Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.
Smith & Nephew's (SNN) STITCH Study Outcome Encouraging
by Zacks Equity Research
This can be considered a major step in Smith & Nephew's (SNN) commitment toward strengthening its Global Sports Medicine and ENT segment.
Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining from several positive developments of late.
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
by Zacks Equity Research
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
Smith & Nephew (SNN) Buys Brainlab, Braces Robotic Ecosystem
by Zacks Equity Research
The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.
Titan Medical (TMDI) Shows Promise on Strategic Developments
by Zacks Equity Research
Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.
Here's Why You Should Invest in Smith & Nephew (SNN) Now
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining investor confidence on consistently positive results.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco